Tyk2-IN-30

CAS No. 1334407-95-2

Tyk2-IN-30( —— )

Catalog No. M11333 CAS No. 1334407-95-2

TYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Tyk2-IN-30
  • Note
    Research use only, not for human use.
  • Brief Description
    TYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM.
  • Description
    TYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM, exhibits excellent selectivity (35-fold for JAK1 and 83-fold for JAK3); potently inhibits IL-23 pathway in cells with EC50 of 66 nM, and has good pharmacokinetic properties; demonstrates dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1334407-95-2
  • Formula Weight
    396.235
  • Molecular Formula
    C18H11Cl2N7
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    3,5-dichloro-4-(4-((6-methylpyrimidin-4-yl)amino)-3H-imidazo[4,5-c]pyridin-2-yl)benzonitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liang J, et al. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4370-4376.
molnova catalog
related products
  • NS-018

    NS-018 (NS018, Ilginatinib) is a potent and highly selective JAK2 inhibitor (IC50=0.72 nM).

  • LY2784544

    LY2784544 (Gandotinib) is a potent, selective and ATP-competitive inhibitor of JAK2V617F.

  • Povorcitinib phospha...

    Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.